Difference between revisions of "Team:SDU-Denmark/Tour12"

Line 2: Line 2:
 
<html>
 
<html>
  
<div class="memberWrapper">
+
 
 
<p> <i> "???" - <b>By Who??</b></i></p>
 
<p> <i> "???" - <b>By Who??</b></i></p>
  

Revision as of 22:52, 16 September 2015

"???" - By Who??

Attributions

Despite our tireless efforts we could not have done this on our own. Therefore we would like to express our gratitude and thank all on the following lists.

Sponsors

Laboratory support

  • Our instructors Postdoc and Ph. D. Mikkel Girke Jørgensen, Academic Assistant Tina Kronborg, Ph. D. student Thøger Jensen Krogh and Stud.cand.scient Patrick Rosendahl Andreassen
  • Medical Laboratory Technician Simon Rose who

General support

  • DTU – for arranging the anually bio brick workshop
  • Vilnius iGEM team – for hosting our visit for three days
  • The SDU iGEM team 2013
  • Uppsala iGEM team - Nordic Meetup
  • Associate professor, MD Søren Thue Lillevang. Department of Clinical Immunology, Odense University Hospital. He attributed to the discussion about medical aspects
  • Associate Professor Jan Nehlin, Department of Clinical Immunology Odense University Hospital.
  • Nancy Rasmussen - for helping us proof reading our wiki.

Technical support

Litterature support

Antibody issue

  • Lubert Stryer JMB, John L. Tymoczko. The Immune System. Biochemistry. 7 ed: W. H. Freeman and Company; 2012.
  • Cowan MK. Host Defenses II - Specific Immunity and Immunization. Microbiology - A Systems Approach. 3 ed: McGraw-Hill; 2012.
  • Chippaux JP, Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon. 1998;36(6):823-46.
  • Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3(1):73-8.
  • Siddiqui MZ. Monoclonal antibodies as diagnostics; an appraisal. Indian J Pharm Sci. 2010;72(1):12-7.
  • Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002;324(1):14-30.
  • Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-87.
  • BioPharma P. What Are Humanized Monoclonal Antibodies 2015 [cited 2015 08/08]. (Link)
  • Payne WJ, Jr., Marshall DL, Shockley RK, Martin WJ. Clinical laboratory applications of monoclonal antibodies. Clin Microbiol Rev. 1988;1(3):313-29.
  • Hnasko RM, Stanker LH. Hybridoma Technology. Methods Mol Biol. 2015;1318:15-28.
  • Stills HF, Jr. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 2005;46(3):280-93.
  • Descartes Rene. Les Méditations métaphysiques’, 1647
  • Bentham Jeremy, Introduction to the Principles of Morals and Legislation, 1789
  • Three RS (Link)
  • Cruelty Free International (Link)
  • Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Demystified …: Monoclonal antibodies. Molecular Pathology. 2000;53(3):111-7.
  • Colas P. The eleven-year switch of peptide aptamers. Journal of biology. 2008;7(1):2.
  • Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. 1996;380(6574):548-50.
  • Borghouts C, Kunz C, Delis N, Groner B. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Molecular cancer research : MCR. 2008;6(2):267-81.
  • Evans D, Johnson S, Laurenson S, Davies AG, Ko Ferrigno P, Wälti C. Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays. Journal of biology. 2008;7(1):3.
  • Li J, Tan S, Chen X, Zhang CY, Zhang Y. Peptide aptamers with biological and therapeutic applications. Current medicinal chemistry. 2011;18(27):4215-22.
  • Swiss Institute of Bioinformatics. 2015. (Link)
  • Key Benefits: Affimers have some simple but essential advantages over antibodies: Avacta Life Sciences; [updated 19-08-2015]. (Link)

P.A.S.T

  • Karimova G, Pidoux J, Ullmann A, Ladant D. A bacterial two-hybrid system based on a reconstituted signal transduction pathway. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(10):5752-6.(Link)
  • Battesti A, Bouveret E. The bacterial two-hybrid system based on adenylate cyclase reconstitution in Escherichia coli. Methods (San Diego, Calif). 2012;58(4):325-34.(Link)
  • SIMON L. DOVE, J. KEITH JOUNG* & ANN HOCHSCHILD - ‘Activation of prokaryotic transcription through arbitrary protein–protein contacts’ - Nature 386, 627-630 (10 April 1997).(Link)
  • J. Keith Joung, Elizabeth I. Ramm, and Carl O. Pabo - ‘A bacterial two-hybrid selection system for studying protein–DNA and protein–protein interactions’ - Proceedings of the National Academy of Science of the United States. vol. 97, (20 june 2000).(Link)

Process

  • World health organization, third edition, 2004 - Visited: 16.09.15.(Link)
  • Lov om miljø og genteknologi - Visited: 16.09.15.(Link)
  • Arbejdstilsynet - Visited: 16.09.15.(Link)
  • E.coli Genome Project, University of Wisconsin - Visited: 16.09.15.(Link)
  • NIH Guidelines for research involving - Visited: 16.09.15.(Link)
  • WO 2001073108 A2 - Patent - Visited: 16.09.15.(Link)
  • Europa-parlementets og rådets direktiv 2009/41/EF - Visited: 16.09.15.(Link)

Results

Practices

What's Next

  • Karimova G, Pidoux J, Ullmann A, Ladant D. - A bacterial two-hybrid system based on a reconstituted signal transduction pathway. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(10):5752-6.(Link)